Scinovex
review Open AccessTop 1% cited

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease

Frontiers in Neuroscience · 2018 · Vol. 12 · pp. 25–25
Fuyuki KametaniMasato Hasegawa

Abstract

The so-called amyloid hypothesis, that the accumulation and deposition of oligomeric or fibrillar amyloid β (Aβ) peptide is the primary cause of Alzheimer's disease (AD), has been the mainstream concept underlying AD research for over 20 years. However, all attempts to develop Aβ-targeting drugs to treat AD have ended in failure. Here, we review recent findings indicating that the main factor underlying the development and progression of AD is tau, not Aβ, and we describe the deficiencies of the amyloid hypothesis that have supported the emergence of this idea.

Alzheimer's disease research and treatmentsComputational Drug Discovery MethodsCholinesterase and Neurodegenerative DiseasesAmyloid (mycology)Biochemistry of Alzheimer's diseaseNeuroscienceDiseaseAlzheimer's diseasePsychologyMedicineAmyloid precursor proteinPathology

Funding

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
Citations
820
FWCI
49.85
field-weighted impact
References
155
Percentile
100%
vs. same field & year
Citations per year
Cited by
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.